Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
VTGN 
VistaGen Therapeutics Inc (VTGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: VTGN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $13
1 Year Target Price $13
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -61.64% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 57.44M USD | Price to earnings Ratio - | 1Y Target Price 13 |
Price to earnings Ratio - | 1Y Target Price 13 | ||
Volume (30-day avg) 4 | Beta 0.69 | 52 Weeks Range 1.90 - 4.21 | Updated Date 06/30/2025 |
52 Weeks Range 1.90 - 4.21 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.67 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) 96633.34% |
Management Effectiveness
Return on Assets (TTM) -33.64% | Return on Equity (TTM) -55.69% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -21532266 | Price to Sales(TTM) 118.19 |
Enterprise Value -21532266 | Price to Sales(TTM) 118.19 | ||
Enterprise Value to Revenue 8.05 | Enterprise Value to EBITDA -0.19 | Shares Outstanding 29157700 | Shares Floating 20485932 |
Shares Outstanding 29157700 | Shares Floating 20485932 | ||
Percent Insiders 0.26 | Percent Institutions 52.9 |
Analyst Ratings
Rating 2 | Target Price 13 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
VistaGen Therapeutics Inc
Company Overview
History and Background
VistaGen Therapeutics Inc. was founded in 2005. The company is focused on developing and commercializing new generation medicines for anxiety, depression, and other central nervous system (CNS) disorders. They are working on a pipeline of product candidates targeting mental health and neurological disorders.
Core Business Areas
- CNS Disorder Therapeutics: VistaGen focuses on developing innovative therapies for central nervous system (CNS) disorders, including anxiety and depression.
- AV-101 (now PH94B): Early-stage development of therapeutics based on the AV-101 compound for various CNS indications.
Leadership and Structure
Shawn Singh is the CEO. The company has a board of directors and various operational departments focused on research, development, and clinical trials.
Top Products and Market Share
Key Offerings
- PH94B (Fasedienol): An investigational pherine nasal spray for the acute treatment of social anxiety disorder (SAD). Currently in Phase 3 clinical trials. No market share data yet as it's pre-commercialization. Competitors would include SSRIs and other anxiety medications like those from Pfizer (PFE), Eli Lilly (LLY), and others.
- AV-101: An oral NMDA receptor glycine site antagonist for neurological and psychiatric disorders. No market share data because it's still in pre-clinical/clinical stages. Competitors include drugs targeting NMDA receptors, and treatments from companies like Janssen (JNJ) for related disorders.
Market Dynamics
Industry Overview
The CNS therapeutics market is large and growing, driven by increasing awareness of mental health disorders and the development of new treatments. It is characterized by high research and development costs and regulatory hurdles.
Positioning
VistaGen is positioned as a clinical-stage biopharmaceutical company focused on innovative therapies for CNS disorders. Their competitive advantage lies in their novel pherine technology and NMDA receptor modulation approach.
Total Addressable Market (TAM)
The total addressable market (TAM) for anxiety and depression is estimated to be in the billions of dollars annually. VistaGen, with its focus on novel treatments like PH94B, aims to capture a portion of this market. The specific TAM opportunity depends on the efficacy and regulatory approval of their products.
Upturn SWOT Analysis
Strengths
- Novel technology platforms (pherine and NMDA)
- Focus on unmet medical needs in CNS disorders
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Pre-commercialization stage
- High cash burn rate
Opportunities
- Positive clinical trial results for PH94B
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into other CNS disorders
- Increasing awareness and acceptance of mental health treatments
Threats
- Clinical trial failures
- Regulatory delays
- Competition from established pharmaceutical companies
- Patent expirations
Competitors and Market Share
Key Competitors
- PFE
- LLY
- JNJ
- ALKS
- SAGE
Competitive Landscape
VistaGen's advantage lies in its novel technology. However, the company faces intense competition from large pharmaceutical companies with established products and resources.
Growth Trajectory and Initiatives
Historical Growth: VistaGen's historical growth is characterized by research and development progress. Milestone payments from licensing agreements will be added to their income once they start. This has been limited thus far.
Future Projections: Future projections depend on the success of PH94B in Phase 3 trials and subsequent regulatory approval. Analyst estimates are contingent on clinical and regulatory outcomes.
Recent Initiatives: Focusing on the Phase 3 clinical program for PH94B, exploring potential partnerships, and continuing to advance their pipeline.
Summary
VistaGen is a high-risk, high-reward clinical-stage biopharmaceutical company. Its innovative technology platforms hold promise for treating CNS disorders. However, its success depends heavily on positive clinical trial outcomes, regulatory approvals, and securing sufficient funding. Investors should consider the significant risks associated with pre-commercialization stage companies. Recent positive clinical trial results may increase the likelihood of its success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- VistaGen Therapeutics Inc. website
- SEC filings
- ClinicalTrials.gov
- Various financial news sources and analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual risk tolerance and due diligence. Market share data is estimated and may not be precise. This analysis is based on publicly available information and current understanding, and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About VistaGen Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2016-05-06 | President, CEO & Director Mr. Shawn K. Singh J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 56 | Website https://www.vistagen.com |
Full time employees 56 | Website https://www.vistagen.com | ||
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline comprises of Fasedienol(PH94B), an investigational pherine nasal spray for the treatment of anxiety in adults with social anxiety disorder which is in Phase III clinical trial; and Itruvone(PH10), an odorless synthetic investigational neuroactive pherine nasal spray for the treatment of major depressive disorder which is in Phase II clinical trial. It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray with a novel for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders that is in Phase II clinical trial; PH15, an investigational pherine nasal spray with a novel for the treatment to improve cognitive impairment caused by mental fatigue and potentially other disorders that is in Phase II clinical trial; and PH284, an odorless and tasteless synthetic investigational pherine nasal spray with a novel for the treatments of the loss of appetite associated with chronic disorders, such as cancer, heart disease, as well as cachexia that is in Phase II clinical trial. In addition, the company is developing an oral candidate, AV-101, an Oral NMDR glycine site antagonist for the treatment of depression and neurological disorders that is in phase I clinical trial. Further, its clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.